Table 1.
Baseline Characteristics and Early Mortality in Adults Initiating Antiretroviral Therapy with Advanced HIV Disease
| Death by Week 48 | |||||
|---|---|---|---|---|---|
| Characteristic | Yes (N=66) |
No (N=771) |
Adjusted HR (95% CI)1,2 |
N (no. events) |
|
| Age (years) | Median (IQR) | 38.5 (31.0, 47.0) | 35 (30, 41) | 0.95 (0.93–0.98) | 837 (66) |
| BMI (kg/m^2) | Median (IQR) | 19.2 (17.6, 21.4) | 20.3 (18.3, 22.7) | 837 (66) | |
| 18.5–25 vs. > 25 | 1.75 (0.61–4.99) | ||||
| < 18.5 vs. > 25 | 1.64 (0.55–4.96) | ||||
| Hemoglobin (g/dL) | Median (IQR) | 10.6 (8.8, 11.8) | 11.3 (10.1, 12.6) | 1.33 (1.17–1.51) | 837 (66) |
| Absolute CD4 count | Median (IQR) | 14.5 (7.0, 19.0) | 19 (9, 33) | 1.46 (1.20–1.78)3 | 837 (66) |
| log 10 HIV-1 RNA/mL | Median (IQR) | 5.4 (4.9, 5.9) | 5.3 (4.9, 5.7) | 0.86 (0.60–1.24) | 837 (66) |
| Sex | N (%) | 837 (66) | |||
| Male | 36 (55%) | 410 (53%) | Reference | ||
| Female | 30 (45%) | 361 (47%) | 1.02 (0.61–1.72) | ||
| Albumin (g/L) | Median (IQR) | 33.0 (28.0, 36.7) | 37.0 (32.1, 41.0) | 1.08 (1.03–1.13) | 834 (66) |
| Absolute neutrophil count (10^9 cells/L) | Median (IQR) | 1.9 (1.2, 3.2) | 1.6 (1.1, 2.3) | 0.80 (0.72–0.88) | 837 (66) |
| Neutrophils (%) | Median (IQR) | 57.5 (43.6, 73.4) | 53.7 (44.2, 63.7) | 0.98 (0.97–1.00) | 827 (66) |
| Serum creatinine (mg/dL) | Median (IQR) | 0.8 (0.6, 0.9) | 0.7 (0.6, 0.9) | 0.99 (0.96–1.01) | 784 (65) |
| White blood cell count (10^9 cells/L) | Median (IQR) | 3.5 (2.5, 4.8) | 3.0 (2.3, 4.0) | 0.80 (0.73–0.89) | 837 (66) |
| CD4 to CD8 ratio (× 100) | Median (IQR) | 3.5 (1.5, 5.1) | 4.2 (2.1, 7.1) | 1.01 (0.95–1.07) | 836 (66) |
| Signs and symptoms (yes vs no): | |||||
| Unknown | 2 (3%) | 6 (1%) | 829 (64) | ||
| Cough lasting 2 or more weeks | 6 (9%) | 131 (17%) | 0.454 (0.19–1.06) | 829 (64) | |
| Headache in past 30 days | 9 (14%) | 101 (13%) | 1.01 (0.49–2.04) | 829 (64) | |
| Fever > 38 C | 1 (1.5%) | 48 (6%) | 0.20 (0.03–1.45) | 829 (64) | |
| Night sweats in past 2 weeks | 8 (12%) | 67 (9%) | 1.28 (0.60–2.71) | 829 (64) | |
| Unintentional weight loss past 30 days | 37 (56%) | 369 (48%) | 1.28 (0.77–2.13) | 829 (64) | |
| Enlarged axillary/cervical lymph nodes | 11 (17%) | 67 (9%) | 2.15 (1.11–4.17) | 829 (64) | |
| Any symptom | 42 (64%) | 475 (62%) | 1.00 (0.59–1.71) | 829 (64) | |
| Any diagnosed WHO stage 3 or 4 condition | 29 (44%) | 287 (37%) | 1.05 (0.63–1.73) | 837 (66) | |
1
Hazard ratios for continuous variables are given per unit decrease, unless otherwise noted
2
Hazard ratios adjusted for age, sex, BMI (categorical), hemoglobin, CD4 count, and log 10 HIV−1 RNA/mL
3
Hazard ratio is per 10 unit decrease